Has Hal Barron’s dream for Oncology imploded as it always was? Oncology - Blenrep, NY-ESO, plus other assets like Otilimab have bankrupted the company as he moves into the board of directors.
Has Wood got the experience and does his role still earn more than Emma?
the pipeline is dry …. What is gonna fail next?
Has Hal Barron’s dream for Oncology imploded as it always was? Oncology - Blenrep, NY-ESO, plus other assets like Otilimab have bankrupted the company as he moves into the board of directors.
Has Wood got the experience and does his role still earn more than Emma?
the pipeline is dry …. What is gonna fail next?
Today's headline - GSK doubles down on vaccines, HIV meds as CEO Emma Walmsley touts 'landmark' 2022.
At least Hal was able to execute a DNA Transfer to Em.Wood has no wood, impotent.
If you work in ONCOLOGY, get out NOW!
Today's headline - GSK doubles down on vaccines, HIV meds as CEO Emma Walmsley touts 'landmark' 2022.
They failed at oncology AGAIN and will be dumping it soon to the highest bidder, who already as sufficient oncology personnel to manage Zejula and Jemperli.
You've been warned, no one to blame but yourself if you are unemployed in Q3.
Also, one cannot forget the "Lilly boys and girls" he brought on to manage the US business; to say the were an inept bunch is being nice.Oncology did not fail AGAIN.....that implies it failed the first time. The previous Oncology business unit had excellent products and a good future but the moron Andrew Witty traded it away to Novartis for their Consumer Division. Also, the Tesaro acquisition is paying off much better than anticipated as some of the risks were mitigated...the recent Jemperli head to head win against Keytruda for lung cancer, and the Zejula sales growth are most notable examples. My recomendation for the person who made this comment is to figure out how to be part of the solution.....not the problem.....or you need to go somewhere else.
Oncology did not fail AGAIN.....that implies it failed the first time. The previous Oncology business unit had excellent products and a good future but the moron Andrew Witty traded it away to Novartis for their Consumer Division. Also, the Tesaro acquisition is paying off much better than anticipated as some of the risks were mitigated...the recent Jemperli head to head win against Keytruda for lung cancer, and the Zejula sales growth are most notable examples. My recomendation for the person who made this comment is to figure out how to be part of the solution.....not the problem.....or you need to go somewhere else.
Also, one cannot forget the "Lilly boys and girls" he brought on to manage the US business; to say the were an inept bunch is being nice.
Oncology did not fail AGAIN.....that implies it failed the first time. The previous Oncology business unit had excellent products and a good future but the moron Andrew Witty traded it away to Novartis for their Consumer Division. Also, the Tesaro acquisition is paying off much better than anticipated as some of the risks were mitigated...the recent Jemperli head to head win against Keytruda for lung cancer, and the Zejula sales growth are most notable examples. My recomendation for the person who made this comment is to figure out how to be part of the solution.....not the problem.....or you need to go somewhere else.
Mic drop! Honesty- a rarity at GSK.Come on...our flagship product was a mediocre TKI in Votrient. We have never been a real player in the oncology space and today is no different. We underpay in commercial versus the biotech's, we can't land experienced oncology talent, and the big pharma, primary care mentality makes Merck look and feel like a startup compared to GSK.
As far as your lame and outdated 'solution vs. problem' statement...very clever...and it's exactly what insecure, talentless organizations say when they don't like hearing the truth and want to live in their insular echo chamber. That is GSK.
Oncology did not fail AGAIN.....that implies it failed the first time. The previous Oncology business unit had excellent products and a good future but the moron Andrew Witty traded it away to Novartis for their Consumer Division. Also, the Tesaro acquisition is paying off much better than anticipated as some of the risks were mitigated...the recent Jemperli head to head win against Keytruda for lung cancer, and the Zejula sales growth are most notable examples. My recomendation for the person who made this comment is to figure out how to be part of the solution.....not the problem.....or you need to go somewhere else.
Come on...our flagship product was a mediocre TKI in Votrient. We have never been a real player in the oncology space and today is no different. We underpay in commercial versus the biotech's, we can't land experienced oncology talent, and the big pharma, primary care mentality makes Merck look and feel like a startup compared to GSK.
As far as your lame and outdated 'solution vs. problem' statement...very clever...and it's exactly what insecure, talentless organizations say when they don't like hearing the truth and want to live in their insular echo chamber. That is GSK.
Oncology unit at GSK is a joke and they should divest of the unit - the leadership from managers to VP of sales to products are hot garbage. They don’t have a clue what they are doing. It’s comical. Bottom tier quote “oncology company” notice in the recent earning statement - did not mention a word about oncology.
